Leerink Swann Initiates ACADIA Pharmaceuticals At Outperform

Loading...
Loading...
Analysts at Leerink Swann initiated coverage on
ACADIA Pharmaceuticals Inc. ACAD
with a Outperform rating. The target price for ACADIA Pharmaceuticals is set to $48. ACADIA Pharmaceuticals shares have gained 92.90% over the past 52 weeks, while the S&P 500 index has surged 12.97% in the same period. ACADIA Pharmaceuticals shares rose 1.33% to $38.00 in pre-market trading.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: InitiationAnalyst RatingsLeerink Swann
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...